Beryl Drugs Beheer

Beheer criteriumcontroles 3/4

We currently do not have sufficient information about the CEO.

Belangrijke informatie

Sanjay Sethi

Algemeen directeur

₹2.1m

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	23.9yrs
Eigendom CEO	17.7%
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	14.7yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Sanjay Sethi's beloning veranderd ten opzichte van Beryl Drugs's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	₹6m
Mar 31 2024	₹2m	n/a	₹8m
Dec 31 2023	n/a	n/a	₹12m
Sep 30 2023	n/a	n/a	₹10m
Jun 30 2023	n/a	n/a	₹11m
Mar 31 2023	₹2m	n/a	₹8m
Dec 31 2022	n/a	n/a	₹2m
Sep 30 2022	n/a	n/a	-₹162k
Jun 30 2022	n/a	n/a	-₹8m
Mar 31 2022	₹2m	n/a	-₹7m
Dec 31 2021	n/a	n/a	-₹674k
Sep 30 2021	n/a	n/a	-₹1m
Jun 30 2021	n/a	n/a	₹8m
Mar 31 2021	₹2m	n/a	₹2m
Dec 31 2020	n/a	n/a	-₹4m
Sep 30 2020	n/a	n/a	-₹2m
Jun 30 2020	n/a	n/a	-₹5m
Mar 31 2020	₹1m	₹1m	₹479k
Dec 31 2019	n/a	n/a	₹7m
Sep 30 2019	n/a	n/a	₹8m
Jun 30 2019	n/a	n/a	₹7m
Mar 31 2019	₹780k	₹780k	₹6m
Dec 31 2018	n/a	n/a	₹8m
Sep 30 2018	n/a	n/a	₹7m
Jun 30 2018	n/a	n/a	₹11m
Mar 31 2018	₹780k	₹780k	₹10m

Compensatie versus markt: Sanjay's total compensation ($USD24.97K) is below average for companies of similar size in the Indian market ($USD42.81K).

Compensatie versus inkomsten: Sanjay's compensation has been consistent with company performance over the past year.

CEO

Sanjay Sethi (61 yo)

23.9yrs

Tenure

₹2,100,000

Compensatie

Mr. Sanjay Sethi serves as the Managing Director and Executive Director of Beryl Drugs Ltd. and was its Director since December 12, 2000. He Joined Beryl Drugs Limited in December 12, 2000.Mr. Sethi has b...

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Sanjay Sethi	MD & Executive Director	23.9yrs	₹2.10m	17.74% ₹ 34.7m
Sudhir Sethi	Non Executive Chairman	23.9yrs	geen gegevens	8.65% ₹ 16.9m
Shreya Saraf	Independent Non-Executive Women Director	5.5yrs	₹35.00k	geen gegevens
Abhinav Naik	Independent Non-Executive Director	5.5yrs	₹35.00k	geen gegevens

14.7yrs

Gemiddelde duur

49.5yo

Gemiddelde leeftijd

Ervaren bestuur: 524606's board of directors are seasoned and experienced ( 14.7 years average tenure).

Beryl Drugs Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Beryl Drugs Limited, Annual General Meeting, Sep 30, 2024

Beryl Drugs Limited, Annual General Meeting, Sep 30, 2024

Beryl Drugs Limited, Annual General Meeting, Sep 30, 2024

Beryl Drugs Limited, Annual General Meeting, Sep 21, 2023

Insufficient new directors

Beryl Drugs Limited, Annual General Meeting, Sep 29, 2022

Recent updates

Investor sentiment improves as stock rises 20%

Investor sentiment improves as stock rises 22%

Beryl Drugs Limited, Annual General Meeting, Sep 30, 2024

Beryl Drugs Limited, Annual General Meeting, Sep 30, 2024

Beryl Drugs Limited, Annual General Meeting, Sep 30, 2024

New minor risk - Profit margin trend

Beryl Drugs Limited to Report Q1, 2025 Results on Aug 09, 2024

Investor sentiment improves as stock rises 20%

Full year 2024 earnings released: EPS: ₹1.52 (vs ₹1.51 in FY 2023)

Beryl Drugs Limited to Report Fiscal Year 2024 Results on May 30, 2024

Investor sentiment improves as stock rises 24%

Now 22% overvalued after recent price rise

Investor sentiment deteriorates as stock falls 17%

Investor sentiment improves as stock rises 23%

Beryl Drugs Limited to Report Q3, 2024 Results on Feb 12, 2024

Third quarter 2024 earnings released: EPS: ₹0.61 (vs ₹0.28 in 3Q 2023)

Now 34% overvalued after recent price rise

New minor risk - Share price stability

Investor sentiment improves as stock rises 19%

Investor sentiment improves as stock rises 17%

Beryl Drugs Limited to Report Q2, 2024 Results on Nov 08, 2023

Now 20% undervalued

Now 20% undervalued

Beryl Drugs Limited, Annual General Meeting, Sep 21, 2023

Investor sentiment improves as stock rises 26%

First quarter 2024 earnings released: EPS: ₹1.05 (vs ₹0.43 in 1Q 2023)

Beryl Drugs Limited to Report Q1, 2024 Results on Aug 12, 2023

Full year 2023 earnings released: EPS: ₹1.52 (vs ₹1.30 loss in FY 2022)

Investor sentiment improves as stock rises 17%

Third quarter 2023 earnings released: EPS: ₹0.28 (vs ₹0.20 loss in 3Q 2022)

Beryl Drugs Limited to Report Q3, 2023 Results on Feb 13, 2023

Insufficient new directors

Beryl Drugs Limited to Report First Half, 2023 Results on Nov 14, 2022

Beryl Drugs Limited, Annual General Meeting, Sep 29, 2022

First quarter 2023 earnings released: EPS: ₹0.43 (vs ₹0.67 in 1Q 2022)

Insufficient new directors

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS ₹0.47 (vs ₹0.095 in FY 2020)

New 90-day low: ₹5.70

Third quarter 2021 earnings released: ₹0.34 loss per share (vs ₹0.18 profit in 3Q 2020)

Beryl Drugs Limited to Report Q3, 2021 Results on Feb 12, 2021

New 90-day high: ₹7.08

New 90-day low: ₹5.47

New 90-day low: ₹6.22

Members of the Sethi family, namely Sangita Sethi, Sanjay Sethi, Sudhir B Sethi, Babulal Sethi and Soniya Sethi made an offer to acquire an additional 26% stake in Beryl Securities Limited (BSE:531582) from Beryl Drugs Limited (BSE:524606) and others for INR 22 million.

First quarter earnings released

Beryl Drugs Limited to Report Q1, 2021 Results on Sep 03, 2020

Full year earnings released - EPS ₹0.09

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd